PIPELINE

POWERED BY
PURPOSE

Every product candidate in our pipeline represents a major step in the right direction for patients and healthcare providers. Our teams have been hard at work to grow our portfolio of acute care and oncology treatments with the goal of improving lives through innovative therapies.

THE TEAMS
AT WORK

 

Medical and Operations

Woodcliff Lake, NJ

Jupiter, FL

Office of Pharmaceutical Development

Cambridge, MA

OUR PORTFOLIO AND PIPELINE CURRENTLY INCLUDES

RYANODEX® (dantrolene sodium) for Injectable Suspension

Learn more about RYANODEX and approved indications

Nerve-Agent Induced Brain Damage Investigational Indication

Prescribing Information

VASOPRESSIN INJECTION

Prescribing Information

PEMFEXY® (pemetrexed injection)

Prescribing Information

BELRAPZO® (bendamustine hydrochloride injection)

Learn more about BELRAPZO® and approved indications

Prescribing Information

Fulvestrant

Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer, Who Have Gone Through Menopause and Have Not Been Previously Treated with Endocrine Therapy Investigational Indication

HR-Positive Advanced Breast Cancer, Who Have Gone Through Menopause and Whose Disease Has Progressed After Endocrine Therapy Investigational Indication

HR-Positive, HER2-Negative Advanced Breast Cancer or Breast Cancer That Has Spread to Other Parts Of The Body (Metastatic), in Combination With Palbociclib or Abemaciclib in Women Whose Disease Has Progressed After Endocrine Therapy  Investigational Indication